{"id":3151,"date":"2021-01-11T20:12:34","date_gmt":"2021-01-12T04:12:34","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=3151"},"modified":"2021-01-11T20:12:34","modified_gmt":"2021-01-12T04:12:34","slug":"continuation-versus-discontinuation-of-renin-angiotensin-system-inhibitors-in-patients-admitted-to-hospital-with-covid-19-a-prospective-randomised-open-label-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/01\/11\/continuation-versus-discontinuation-of-renin-angiotensin-system-inhibitors-in-patients-admitted-to-hospital-with-covid-19-a-prospective-randomised-open-label-trial\/","title":{"rendered":"Continuation versus Discontinuation of Renin\u2013Angiotensin System Inhibitors in Patients Admitted to Hospital with COVID-19: A Prospective, Randomised, Open-Label Trial"},"content":{"rendered":"<p>A prospective, randomized, open-label trial concluded that renin\u2013angiotensin system inhibitors, which are commonly used to treat hypertension, could safely be continued in patients hospitalized with COVID-19. Between March 31 and August 20, 2020, 152 participants were randomly assigned to either continue or discontinue renin\u2013angiotensin system inhibitor therapy. 16 (21%) participants in the continuation arm versus 14 (18%) in the discontinuation arm required intensive care unit admission or invasive mechanical ventilation, and 11 (15%) of 75 participants in the continuation arm versus 10 (13%) in the discontinuation arm died. 29 (39%) participants in the continuation arm and 28 (36%) participants in the discontinuation arm had at least one adverse event.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p><i>Cohen et al. (Jan 7, 2021). Continuation versus Discontinuation of Renin\u2013Angiotensin System Inhibitors in Patients Admitted to Hospital with COVID-19: A Prospective, Randomised, Open-Label Trial. The Lancet Respiratory Medicine. <\/i><a href=\"https:\/\/doi.org\/10.1016\/S2213-2600(20)30558-0\">https:\/\/doi.org\/10.1016\/S2213-2600(20)30558-0<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A prospective, randomized, open-label trial concluded that renin\u2013angiotensin system inhibitors, which are commonly used to treat hypertension, could safely be continued in patients hospitalized with COVID-19. Between March 31 and August 20, 2020, 152 participants were randomly assigned to either continue or discontinue renin\u2013angiotensin system inhibitor therapy. 16 (21%) participants in the continuation arm versus&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/01\/11\/continuation-versus-discontinuation-of-renin-angiotensin-system-inhibitors-in-patients-admitted-to-hospital-with-covid-19-a-prospective-randomised-open-label-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-3151","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=3151"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3151\/revisions"}],"predecessor-version":[{"id":3152,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3151\/revisions\/3152"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=3151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=3151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=3151"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=3151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}